Characterization of Post-Operative Risk Associated With Prior Drug-Eluting Stent Use

JACC: Cardiovascular Interventions

Volumn 2, Issue 6, 2009, Pages 542-549

  Anwaruddin, Saif ^a   Askari, Arman T ^a   Saudye, Hammad ^a   Batizy, Lilian ^a   Houghtaling, Penny L ^a   Alamoudi, Mohammad ^b   Militello, Michael ^a   Muhammad, Kamran ^a   Kapadia, Samir ^a   Ellis, Stephen G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

drug eluting stents; perioperative risk; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

AGED; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; CORONARY ARTERY THROMBOSIS; DRUG ELUTING STENT; EMERGENCY SURGERY; FEMALE; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL RISK; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DATABASES AS TOPIC; DRUG-ELUTING STENTS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE; THROMBOSIS; TIME FACTORS;

EID: 66949155358     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.03.014     Document Type: Article

References (22)

1. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
2. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
3. Ong A.T., McFadden E.P., Regar E., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
4. Wilson S.H., Fasseas P., Orford J.L., et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 42 (2003) 234-240
5. Kaluza G.L., Joseph J., Lee J.R., Raizner M.E., and Raizner A.E. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 35 (2000) 1288-1294
6. Riddell J.W., Chiche L., Plaud B., and Hamon M. Coronary stents and noncardiac surgery. Circulation 116 (2007) e378-e382
7. Nasser M., Kapeliovich M., and Markiewicz W. Late thrombosis of sirolimus-eluting stents following noncardiac surgery. Catheter Cardiovasc Interv 65 (2005) 516-519
8. Compton P.A., Zankar A.A., Adesanya A.O., Banerjee S., and Brilakis E.S. Risk of noncardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol 98 (2006) 1212-1213
9. Schouten O., van Domburg R.T., Bax J.J., et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 49 (2007) 122-124
10. Rabbitts J.A., Nuttall G.A., Brown M.J., et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 109 (2008) 596-604
11. Lee T.H., Marcantonio E.R., Mangione C.M., et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 100 (1999) 1043-1049
12. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 116 (2007) 2634-2653
13. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
14. Hanley J.A., Negassa A., Edwardes M.D., and Forrester J.E. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 157 (2003) 364-375
15. Goldman L., Caldera D.L., Nussbaum S.R., et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 297 (1977) 845-850
16. Goldman L., Caldera D.L., Southwick F.S., et al. Cardiac risk factors and complications in non-cardiac surgery. Medicine (Baltimore) 57 (1978) 357-370
17. Theroux P., Waters D., Lam J., Juneau M., and McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 327 (1992) 141-145
18. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
19. Anand S.X., Kim M.C., Kamran M., et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 100 (2007) 417-424
20. Dahl O.E. Mechanisms of hypercoagulability. Thromb Haemost 82 (1999) 902-906
21. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
22. Hodgson J.M., Stone G.W., Lincoff A.M., et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv 69 (2007) 327-333